Restricted Diet for ADHD?

Topics: ADHD | Child Psychiatry | Research Updates

Stimulants in the Treatment of ADHD

Topics: ADHD | Child Psychiatry | Free Articles

Neurofeedback as a Treatment for ADHD

Topics: ADHD | Brain Devices | Child Psychiatry | Neuroscience in Psychiatry

Neurofeedback, also known as “EEG biofeedback,” has been around for a long time, but its history is checkered. Clinicians have hawked devices for treating ADHD and other psychiatric conditions in the absence of reliable efficacy data. Since the treatment is rarely covered by insurance companies, families may pay several thousand dollars for a typica

ADHD as an Executive Function Disorder

Topics: ADHD | Diagnostic Testing

Dr. Barkley’s Suggested Changes toADHD in DSM-5 Add our understanding that ADHD is an executive function and self regulation disorder into the text. It’s not a good idea to change the name (for legal reasons), but DSM needs to explain that this is so much more than simply an attention problem. Get rid of subtyping. The subtypes are really

TV, Video Games, And Attention Problems

Topics: ADHD | Child Psychiatry

What is the Minimum Effective Dose of OROS Methylphenidate for Adolescents?

Topics: ADHD | Child Psychiatry

Is Intuniv (guanfacine XR) effective for ADHD?

Topics: ADHD

Study Investigates Long-Term Course of ADHD

Topics: ADHD

The Latest on ADHD

Topics: ADHD | Child Psychiatry

The last time we did an entire issue on ADHD was in September of 2006. In this brief article, we’ll bring you up to date on some recent developments. 1. Vyvanse (lisdexamfetamine) was approved for the treatment of ADHD in 6-12 year olds in 2007, and more recently was approved for ADHD in adults. It is essentially a 12 hour form of amphetamine, and

FDA orders consumer medication guides for stimulants

Topics: ADHD

Vyvanse Approved for ADHD

Topics: ADHD

Psychostimulants and ADHD

Topics: ADHD

Since our last issue on ADHD in April of 2005, three new psychostimulant formulations have been approved (Daytrana, the Ritalin patch, and Focalin XR), and one older medication received a new indication (Adderall XR is now indicated for adult ADHD). The bigger news over the past year, however, was two safety warnings added to the product labeling of

Daytrana: A Long and Winding Road to Approval

Topics: ADHD

On April 6, 2006, the FDA announced the approval of Daytrana, a transdermal patch version of Ritalin (methylphenidate). While you wouldn’t know it by the gushy promotional copy on Daytrana’s website (www.daytrana.com), the Ritalin patch just barely squeaked through the FDA approval process. The product was originally submitted for FDA approval in

Sparlon and ADHD: The Power of a 7-Year Old

Topics: ADHD

Rarely has a 7-year old with a rash caused the stock price of a major corporation to gyrate so dramatically. On March 23, 2006, the FDA rejected Cephalon’s application for Sparlon, a renamed Provigil that is effective for treating ADHD. Immediately, the company’s stock lost about 10% of its value, or about $18 million overall; later in the day, i

A Patient’s Perspective: The Value of an ADHD Diagnosis

Topics: ADHD

Mr. H., now 49, was first diagnosed with ADHD at the age of 40, when he was evaluated at the suggestion of an old friend, a psychologist who had known him in grade school. “I was a poster child for ADHD, but it took me a while to accept that ADHD was a real disease. Over time, it helped me see much more deeply into the problems I had as a kid, but

Stimulants: The Case for Caution

Topics: ADHD | Child Psychiatry

Dopamine: Getting Reaquainted

Topics: ADHD

Dopamine is the new serotonin: everyone is talking about it. Depending on what authority you read, dopamine is central to schizophrenia, ADHD, depression, sexuality, and cognition. Dopamine (DA) is one of the catecholamines, a family of neurotransmitters within the larger category of monoamines. Like all monoamines, dopamine has a single amine (NH2)